Information Provided By: 
Fly News Breaks for June 18, 2019
BLUE
Jun 18, 2019 | 09:37 EDT
As previously reported, Maxim analyst Jason McCarthy upgraded Bluebird Bio to Buy from Hold with a $160 price target. The analyst acknowledges that the company's commercial delay in the launch of its Zynteglo in Europe is a "speed bump", but believes that pricing of the drug is "reasonable" and valuation on the stock is "attractive" after the Zynteglo timing-related update from the company . McCarthy adds that tBluebird Bio's U.S. filing for Zynteglo could come this year with approval expected to take place in 2020.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
